AstraZeneca PLC's latest marketcap:
As of 07/04/2025, AstraZeneca PLC's market capitalization has reached $216.08 B. According to our data, AstraZeneca PLC is the 66th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 216.08 B |
| Revenue (ttm) | 54.98 B |
| Net Income (ttm) | 7.77 B |
| Shares Out | 1.55 B |
| EPS (ttm) | 4.97 |
| Forward PE | 15.46 |
| Ex-Dividend Date | 02/21/2025 |
| Earnings Date | 07/24/2025 |
AstraZeneca PLC's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/04/2025 | $216.08 B | 8.56% | 66 |
| 12/31/2024 | $203.11 B | -2.65% | 57 |
| 12/29/2023 | $208.65 B | -0.6% | 52 |
| 12/30/2022 | $209.91 B | 20.44% | 42 |
| 12/31/2021 | $174.28 B | 32.86% | 74 |
| 12/31/2020 | $131.17 B | 1.42% | 95 |
| 12/31/2019 | $129.34 B | 34.47% | 71 |
| 12/31/2018 | $96.18 B | 9.54% | 78 |
| 12/29/2017 | $87.81 B | 27.12% | 109 |
| 12/30/2016 | $69.07 B | -19.47% | 112 |
Company Profile
AstraZeneca PLC Overview
AstraZeneca PLC is a leading biopharmaceutical company specializing in the discovery, development, manufacture, and commercialization of prescription medicines.
Key Products
- Oncology: Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex
- Cardiovascular & Renal: Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa
- Respiratory & Immunology: Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra
- Vaccines & Immune Therapies: Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Beyfortus, Synagis, FluMist, Evusheld
- Rare Diseases: Wainua, Atacand, Plendil, Modip, Splendil, Munobal, Flodil
Therapeutic Areas
AstraZeneca's products cater to multiple therapeutic areas, including:
- Oncology
- Cardiovascular, Renal & Metabolism
- Respiratory & Immunology
- Vaccines & Immune Therapies
- Rare Diseases
Global Presence
The company serves primary and specialty care physicians through distributors and local representative offices across:
- United Kingdom
- United States
- Europe
- Asia
Company Background
Originally known as Zeneca Group PLC, the company rebranded as AstraZeneca PLC in April 1999. Founded in 1992, it is headquartered in Cambridge, United Kingdom.
Frequently Asked Questions
-
What is AstraZeneca PLC's (AZN) current market cap?As of 07/04/2025, AstraZeneca PLC (including the parent company, if applicable) has an estimated market capitalization of $216.08 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does AstraZeneca PLC (AZN) rank globally by market cap?AstraZeneca PLC global market capitalization ranking is approximately 66 as of 07/04/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.